about
Overcoming the challenges of conducting research with people who have advanced heart failure and palliative care needs.Patients' perception of implantable cardioverter defibrillator deactivation at the end of life.Understanding dietary decision-making in patients attending a secondary prevention clinic following myocardial infarction.The challenge of patients' unmet palliative care needs in the final stages of chronic illness.Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self-report and bio-chemical validation.An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis.Female gender doubles pre-hospital delay times for patients experiencing ST segment elevation myocardial infarction in Saudi Arabia.'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study.Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial.'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constitutedAn exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionalsFighting Over Food: Patient and Family Understanding of Cancer CachexiaThe experience of cancer cachexia: A qualitative study of advanced cancer patients and their family membersWhy people experiencing acute myocardial infarction delay seeking medical assistanceDifficult asthma: people's perspectives on taking corticosteroid therapyMaximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2Co-design of a patient and family-initiated escalation of care intervention to detect and refer patient deterioration: Research protocol
P50
Q37844313-558323BD-6C24-48FC-92FB-85C109F3A1A4Q38252697-4F59E092-E26C-499B-83D1-1320EBE9944EQ39753534-C79F92C9-9DCC-472E-A64D-91DF47F515C2Q40189963-4D5990F6-F62B-4719-BC45-685244D2AD83Q43908073-51B05B8E-25CC-4004-A71F-04BB5850D242Q43998363-9F0245BD-AECD-4212-BDB6-5A4E19FD0BD9Q47712900-7A2663FB-6C35-40D3-B9CB-B65EBCA37152Q48187951-7BDD4CBA-9AC1-4375-8650-87B416392DA0Q48419926-7D147D79-1376-4146-AAF2-7940FCA739B6Q57314058-A473F7CB-CA2E-4EBB-AFEB-6F0F59894660Q59650754-A2BC68F2-7718-4382-AF31-959454889AACQ59650761-5F142B87-78AB-4A87-8B05-F912E7259DDEQ59650765-A751D324-B239-498A-8F43-F3345FED9100Q79301008-1E495386-F318-4254-9F2A-A8C1464AE714Q80369422-D28A67D8-B592-4AF0-B06B-8B3808C61485Q87680248-F5135A1F-3EBC-4BD3-B1D4-CD9451615575Q90583775-6E670406-01B0-4CBA-BAA3-28A1789E4E30
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Donna Fitzsimons
@ast
Donna Fitzsimons
@en
Donna Fitzsimons
@es
Donna Fitzsimons
@nl
type
label
Donna Fitzsimons
@ast
Donna Fitzsimons
@en
Donna Fitzsimons
@es
Donna Fitzsimons
@nl
prefLabel
Donna Fitzsimons
@ast
Donna Fitzsimons
@en
Donna Fitzsimons
@es
Donna Fitzsimons
@nl
P106
P1153
55359154300
P31
P496
0000-0002-8299-682X